Abstract:Our study indicated that the 14‐gene‐related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. We found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune‐related cells and pathways in different risk groups. Background Breast cancer (BC), a malignant tumor, is a significant cause of death and disability among women globally. Recent research indicates that copy number variation plays a crucial role in tumor development. In this study, we employed the Single‐Cell Variational Aneuploidy Analysis (SCEVAN) algorithm to differentiate between malignant and non‐malignant cells, aiming to identify genetic signatures with prognostic relevance for predicting patient survival. Methods We analyzed gene expression profiles and associated clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Using the SCEVAN algorithm, we distinguished malignant from non‐malignant cells and investigated cellular interactions within the tumor microenvironment (TME). We categorized TCGA samples based on differentially expressed genes (DEGs) between these cell types. Subsequent Kyoto Encyclopedia of Genes and Genomes pathway analysis was conducted. Additionally, we developed polygenic models for the DEGs using least absolute shrinkage and selection operator‐penalized Cox regression analysis. To assess the prognostic accuracy of these characteristics, we generated Kaplan–Meier and receiver operating characteristic curves from training and validation datasets. We also monitored the expression variations of prognostic genes across the pseudotime of malignant cells. Patients were divided into high‐risk and low‐risk groups based on median risk scores to compare their TME and identify potential therapeutic agents. Lastly, polymerase chain reaction was used to validate seven pivotal genes. Results The SCEVAN algorithm identified distinct malignant and non‐malignant cells in GSE180286. Cellchat analysis revealed significantly increased cellular communication, particularly between fibroblasts, endothelial cells and malignant cells. The DEGs were predominantly involved in immune‐related pathways. TCGA samples were classified into clusters A and B based on these genes. Cluster A, enriched in immune pathways, was associated with poorer prognosis, whereas cluster B, predominantly involved in circadian rhythm pathways, showed better outcomes. We constructed a 14‐gene prognostic signature, validated in a 1:1 internal TCGA cohort and external GEO datasets (GSE42568 and GSE146558). Kaplan–Meier analysis confirmed the prognostic signature's accuracy (p

Bioinformatics Analysis of Pivotal Module and Biomarkers Related to the Prognosis of Breast Cancer Based on Single-cell Transcriptome Data

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis

Immune Microenvironment-Related Genes Contribute to Clinical Prognosis in Patients with Triple-Negative Breast Cancer

Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer

Tumor Characterization in Breast Cancer Identifies Immune-Relevant Gene Signatures Associated With Prognosis

Tumor Microenvironment-Related Multigene Prognostic Prediction Model for Breast Cancer

The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis

Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis

Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio

Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction

Development a Prognostic Model Integrating lncRNA/ mRNA novel Biomarkers Identified by Bioinformatics Analysis and Experiments in Breast Cancer

Correction To: Identification of a Five Genes Prognosis Signature for Triple-Negative Breast Cancer Using Multi-Omics Methods and Bioinformatics Analysis

Multivariate Analysis of Prognostic Factors for Breast Cancer

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

Integrating Single-Cell and Bulk Expression Data to Identify and Analyze Cancer Prognosis-Related Genes

Conjoint analysis of circulating tumor cells and solid tumors for exploring potential prognostic markers and constructing a robust novel predictive signature for breast cancer

A Breast Cancer Classification and Immune Landscape Analysis Based on Cancer Stem-Cell-related Risk Panel

Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer